Literature DB >> 12814868

Exploration of critical parameters for transient retrovirus production.

Marcio C Bajgelman1, Eugenia Costanzi-Strauss, Bryan E Strauss.   

Abstract

The pCL system was developed to aid in the production of retrovirus that encodes cytotoxic or cytostatic cDNA's. A principal feature of this system is the transient production of virus after co-transfection of the viral and packaging vectors in the 293T cell line. This approach obviates the need for selection of the producer cells, thus minimizing potential affects of the encoded genes. However, the transient nature of this system also creates a number of experimental variables. In this study we have examined and optimized elements related to the production of the pCL retrovirus. For example, co-transfection of the packaging sequence along with the viral vector has been optimized in terms of both the total amount of DNA transfected and the relative proportion of each plasmid. We have also tested the affect of increased synthesis of viral proteins in the producer cells and the kinetics of virus accumulation in the supernatant. These findings may be of interest to those who use pCL or any transient packaging system in their gene transfer studies. In addition, these studies may aid in the validation and development of transient retrovirus production systems for clinical applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814868     DOI: 10.1016/s0168-1656(03)00103-2

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  8 in total

1.  Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio.

Authors:  Yong Chen; William M Miller; Ashok Aiyar
Journal:  Biotechnol Prog       Date:  2005 Jan-Feb

2.  Efficient large volume lentiviral vector production using flow electroporation.

Authors:  Scott R Witting; Lin-Hong Li; Aparna Jasti; Cornell Allen; Kenneth Cornetta; James Brady; Rama Shivakumar; Madhusudan V Peshwa
Journal:  Hum Gene Ther       Date:  2011-10-24       Impact factor: 5.695

3.  Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

Authors:  Christian A Merkel; Rafael B da Silva Soares; Anna Carolina V de Carvalho; Daniela B Zanatta; Marcio C Bajgelman; Paula Fratini; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

4.  Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo.

Authors:  Juliana G Xande; Ana P Dias; Rodrigo E Tamura; Mario C Cruz; Bárbara Brito; Robledo A Ferreira; Bryan E Strauss; Eugenia Costanzi-Strauss
Journal:  Gene Ther       Date:  2019-08-22       Impact factor: 5.250

5.  Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

Authors:  Fabricio de Carvalho; Erico T Costa; Anamaria A Camargo; Juliana C Gregorio; Cibele Masotti; Valeria C C Andrade; Bryan E Strauss; Otavia L Caballero; Djordje Atanackovic; Gisele W B Colleoni
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

6.  S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.

Authors:  Camila L Amaral; Lidia B Freitas; Rodrigo E Tamura; Mariana R Tavares; Isadora C B Pavan; Marcio C Bajgelman; Fernando M Simabuco
Journal:  BMC Cancer       Date:  2016-08-05       Impact factor: 4.430

7.  Serial bone marrow transplantation reveals in vivo expression of the pCLPG retroviral vector.

Authors:  Paula Fratini; Bryan E Strauss
Journal:  Virol J       Date:  2010-01-22       Impact factor: 4.099

8.  Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF.

Authors:  Andrea J Manrique-Rincón; Camila M Beraldo; Jessica M Toscaro; Marcio C Bajgelman
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.